Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

Cited by (759)

Items 601–700 of 759

1. Tocilizumab en pacientes con artritis reumatoide activa y respuesta inadecuada a fármacos antirreumáticos modificadores de la enfermedad o antagonistas del factor de necrosis tumoral: subanálisis de los datos españoles de un estudio abierto cercano a la práctica clínica habitual
   Jose-Maria Alvaro-Gracia, A. Fernández-Nebro, A. García-López, M. Guzmán, F. Blanco, F. J. Navarro, Sagrario Bustabad, Y. Armendáriz, J. Román-Ivorra · 2014 · Reumatología Clínica
2. Ethnopharmacological and Scientific Validation of Caryota mitis Lour Fruit Peel for Osteoarthritis and Gout Management.
   Trinh Thi Nhat Pham, Tong Thanh Danh, D. C. Tai, T. V. Phung, L. Truong, Hang Thi Le Dang, Dung Truong, Le-Tien Dung · 2025 · Journal of Ethnopharmacology
3. Comparative study of the clinical efficacy of the first domestic bioanalogue of tocilizumab based on the results of a randomized clinical trial of phase III
   E. V. Akatova, Y. Bakhareva, O. V. Bugrova, I. B. Vinogradova, E. Gerasimova, Yu. E. Drevina, O. Ershova, E. Zonova, Yu. I. Ivanova, E. Ilivanova et al. · 2024 · Modern Rheumatology Journal
4. Non-TNF biologics and their biosimilars in rheumatoid arthritis
   Tsz-Ching Mok, Chi C. Mok · 2024 · Expert Opinion on Biological Therapy
5. A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors
   G. Inanç, M. Terzioğlu, Y. Karabulut, Z. Yilmaz, E. Tarhan, M. E. Enecik, A. Şahin, A. Kucuk, A. Ayan, M. Özgen et al. · 2023 · Turkish Journal of Medical Sciences
6. The Efficacy of Sequential Biologic Agents in Refractory Rheumatoid Arthritis after Failure of Initial DMARD and anti-Tumor Necrosis Factor Therapy
   A. Versace, C. O. Aragona, Daniela La Rosa, Marianna Chiappalone, M. Tringali, Alberta De Gaetano, C. Moore, D. Sangari, W. Roberts, G. Bagnato · 2021 · Rheumato
7. Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme
   D. Scott, F. Ibrahim, H. Hill, B. Tom, Louise Prothero, Rhiannon R. Baggott, A. Bosworth, J. Galloway, S. Georgopoulou, N. Martin et al. · 2021 · Programme Grants for Applied Research
8. Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post hoc multicohort analysis
   A. Abuhelwa, David J. R. Foster, Arkady T. Manning-Bennett, M. Sorich, S. Proudman, M. Wiese, A. Hopkins · 2021 · Therapeutic Advances in Musculoskeletal Disease
9. Previously reported placebo-response-associated variants do not predict patient outcomes in inflammatory disease Phase III trial placebo arms
   Asher Haug-Baltzell, T. Bhangale, Diana Chang, A. Dressen, B. Yaspan, W. Ortmann, M. Brauer, J. Hunkapiller, J. Reeder, Kiran Mukhyala et al. · 2018 · Genes and Immunity
10. On the Mathematical Model of Drug Treatment of Rheumatoid Arthritis
    K. Odisharia, V. Odisharia, P. Tsereteli, N. Janikashvili · 2017 · Springer Proceedings in Mathematics & statistics
11. Eficacia a 2 años de tocilizumab en pacientes con artritis reumatoide activa en la práctica clínica habitual
    Irene Notario Ferreira, M. González, P. Garrido, Alfonso Joaquín González Utrilla, A. Sánchez, M. J. Pino, Evelyn Suero Rosario, C. Hernández, I. A. Oñate, Lorena Pérez Albaladejo et al. · 2017
12. Decrease of Tocilizumab Dose in Patients with Rheumatoid Arthritis: A Pilot Study
    M. Fechtenbaum, P. Lasselin-Boyard, S. Salomon, G. Jelin, F. Millot, F. Grados, P. Fardellone, V. Goëb · 2016 · Pharmacology
13. Pharmacological Properties of Monoclonal Antibodies Directed Against Interleukins
    Kaloyan Georgiev, Marieta Georgieva · 2015 · InTech eBooks
14. Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab
    A. Negoescu, A. Östör · 2014 · Rheumatology and Therapy
15. IL-6 inhibition improves nitric oxide in rheumatoid arthritis
    Jaspreet Kaur, A. Syngle, P. Krishan, K. Vohra, N. Garg, L. Kaur, M. Chhabra · 2014 · Internet Journal of Rheumatology and Clinical Immunology
16. Nichtinterventionelle Phase-IV-Studien zur Behandlung der rheumatoiden Arthritis mit Biologicals in Deutschland
    J. Ruof, C. Iking-Konert, S. Simianer, G. Burmester · 2013 · Zeitschrift für Rheumatologie (Print)
17. Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data
    Y. Nakashima, M. Kondo, T. Fukuda, H. Harada, T. Horiuchi, T. Ishinishi, H. Jôjima, K. Kuroda, H. Miyahara, M. Maekawa et al. · 2013 · Modern Rheumatology
18. Remission of arthritis but persistent cutaneous lesions following tocilizumab treatment in a RA-patient suffering from concomitant psoriasis
    W. Hartung, B. Ehrenstein, R. Wallisch, M. Fleck · 2013
19. The role of tocilizumab monotherapy in the management of rheumatoid arthritis: a review
    M. Nisar, A. Östör · 2012
20. The Role of Tocilizumab in the Treatment of Rheumatoid Arthritis
    Y. Hirabayashi · 2012 · InTech eBooks
21. Biothérapies dans les rhumatismes inflammatoires
    J. Damiano · 2011 · EMC - Podologie
22. New biologics for rheumatoid arthritis.
    E. Choy · 2011 · The Journal of the Royal College of Physicians of Edinburgh
23. [Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model].
    V. Brodszky · 2011 · Orvosi Hetilap
24. Annual drug update: 2010 in review.
    Jennifer M. Belavic · 2011 · The Nurse Practitioner
25. Tocilizumab
    P. Roll, A. Rubbert-Roth, H. Tony · 2010 · Zeitschrift für Rheumatologie (Print)
26. Empfehlungen der Deutschen Gesellschaft für Rheumatologie zum Einsatz von Tocilizumab bei der rheumatoiden Arthritis (Februar 2010)
    A. Gause, A. Rubbert-Roth, H. Michels, M. Gaubitz, W. Mayet, Und Die Kommission Pharmakotherapie der DGRh · 2010 · Zeitschrift für Rheumatologie (Print)
27. The contribution of Asian researchers to the field of rheumatology
    Y. Yamano, K. Nishioka · 2010 · Nature Reviews Rheumatology
28. Pharmacotherapy Options in Rheumatoid Arthritis: Focus on Tocilizumab, a Recombinant Humanized Anti-Interleukin-6 Receptor Antibody
    Yoshiyuki Ohsugi, Tadamitsu Kishimoto · 2009 · Clinical Medicine Therapeutics
29. Toxidermia under treatment with tocilizumab for rheumatoid arthritis.
    M. Fechtenbaum, C. Banse, Pauline Boyard-Lasselin, V. Goëb · 2015 · Joint, bone, spine : revue du rhumatisme
30. Neue Arzneimittel 2009
    Uwe Fricke, U. Schwabe · 2010 · Springer eBooks
31. Inhibition of interleukin 6, a new therapeutic option in rheumatoid arthritis
    R. Alonso, Mario Agudo Bilbao · 2009 · Reumatología Clínica (English Edition)
32. Monoclonal Antibodies as Therapeutic Agents
    Manzoor M. Khan · 2008 · Springer eBooks
33. Effect of Interleukin‐6 Inhibitors on Rheumatoid Arthritis Pain: Overview of Evidence and Mechanistic Pathways
    Andrej Belančić, Seher Sener, Almir Fajkić, Ines Potočnjak, Mirjana Stanić Benić, Marijana Vučković, Yusuf Ziya Şener, Marija Rogoznica Pavlović, Antonio Markotić, Josipa Radić et al. · 2026 · Pharmacology Research & Perspectives
34. Efficacy of pharmacological interventions and therapeutic exercises for rheumatoid arthritis: a systematic review and meta-analysis
    Timothy Adeyemi, Vitalis Ikenna Chukwuike, Motunrayo Adebukunola Oladimeji, Ufuoma Shalom Ahwinahwi, Victor Ayodeji Ayeni, Aisha Adam Abdullahi, Abdulmuminu Isah, Love Bukola Ayamolowo, Oluchukwu Perpetual Okeke, Olunike Rebecca Abodunrin et al. · 2025 · Frontiers in Pharmacology
35. Effectiveness of Low‐Intensity Exercise in Mitigating Active Arthritis Exacerbation in a Mouse Rheumatoid‐Arthritis Model
    K. Ozone, Tatsunori Kumagai, Kouhei Arakawa, T. Sugasawa, Wenchao Gu, S. Kawabata, Naoki Shimada, H. Takahashi, M. Yoneno, Y. Minegishi et al. · 2025 · Journal of Orthopaedic Research
36. Designing target trials using electronic health records: A case study of second-line disease-modifying anti-rheumatic drugs and cardiovascular disease outcomes in patients with rheumatoid arthritis
    A. Rivera, Jacob B. Pierce, Arjun Sinha, Anna E. Pawlowski, D. Lloyd-Jones, Yvonne C. Lee, M. Feinstein, Lucia Petito · 2024 · PLoS ONE
37. Comparative Efficacy of bDMARDs and tsDMARDs for the Treatment of Rheumatoid arthritis: A Systematic Review and Network Meta-Analysis
    Penghua Shi, Li Wang, Jiafang He, Yun Lu · 2023 · International Journal of Biology and Life Sciences
38. Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry.
    O. Karadag, B. Farisoğulları, B. Yağız, A. Erden, Z. Ademoğlu, G. Kimyon, N. Bilge, O. C. Içaçan, L. Kılıç, B. N. Coşkun et al. · 2023 · Clinical and Experimental Rheumatology
39. Tocilizumab as a first-line biologic treatment in rheumatoid arthritis patients – the impact of concomitant methotrexate treatment and Rheumatic Disease Comorbidity Index on the clinical response – results from the multicenter observational ACT-POL study
    M. Stajszczyk, S. Jeka, A. Juś, K. Pawlak-Buś · 2022 · Rheumatology
40. Efficacy and Safety of Opinercept Tumor Necrosis Factor Inhibitor Therapy for Drug-Refractory Rheumatoid Arthritis: A Randomized Clinical Trial.
    Toong-Hua Liang, Chyou-Shen Lee, Shinn-Shing Lee, Chien-Sheng Wu, Kun-Hung Chen, P. Hsu, Hsiao-Yi Lin · 2020 · Archives of Rheumatology
41. Autoantibodies and Cytokines in Pathogenesis of Rheumatoid Arthritis
    Mohd Wajid Ali Khan, Wahid Ali Khan · 2018 · Autoantibodies and Cytokines
42. Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice.
    I. N. Ferreira, M. González, P. Garrido, A. Utrilla, A. G. Sánchez, M. Pino, E. Rosario, C. Hernandez, I. A. Oñate, L. Albaladejo et al. · 2017
43. Tocilizumab-induced mucosal ulcers in a patient with relapsing polychondritis: An adverse drug reaction?
    G. Vitiello, B. Palterer, P. Parronchi, D. Cammelli · 2016 · Seminars in Arthritis & Rheumatism
44. Polyarthrite rhumatoïde de l’adulte : stratégies thérapeutiques
    B. Combe, C. Lukas, J. Morel · 2015 · EMC - Appareil locomoteur
45. Rheumatoide Arthritis – Renale Manifestationen
    K. Triantafyllias, A. Schwarting · 2014 · Dialyse aktuell
46. Personalized medicine in rheumatology
    Zoltán Szekanecz · 2013 · Orvosi Hetilap
47. Biologic Treatment in Rheumatoid Arthritis
    K. Chatzidionysiou · 2012
48. Nicht-TNF-Biologika in der Therapiestrategie bei rheumatoider Arthritis
    J. Wollenhaupt, K. Krüger · 2010 · Zeitschrift für Rheumatologie (Print)
49. De nouvelles cibles cytokiniques dans la polyarthrite rhumatoïde : le tocilizumab et les autres inhibiteurs des cytokines
    Ghita Harifi, Emmanuel Chatelus, Christelle Sordet, Jacques‐Eric Gottenberg, Jean Sibilia · 2010 · Revue du Rhumatisme
50. La inhibición de la interleucina-6, una nueva opción terapéutica en la artritis reumatoide
    R. B. Alonso, Mario Agudo Bilbao · 2009
51. Biological Modifiers of Inflammatory Diseases
    W. Chatham · 2019 · Clinical Immunology
52. 272 – Rheumatoid Arthritis
    J. O'Dell · 2012
53. Tocilizumab-associated oral ulcerations: a case report and scoping review
    Suad Aljohani, E. Nafea · 2026 · Frontiers in Medicine
54. Pretreatment gut microbiome composition as a pharmacomicrobiomic prognosticator of conventional and biologic DMARD response in rheumatoid arthritis: A critical narrative review
    Ali Saad Al-Budairi, A. S. Al-Karawi, A. Atoom · 2026 · Comparative Immunology Reports
55. Glycan-based biological degraders targeting the cytokine immune axis
    Michelle Seifert, Tim Kollenkirchen, Andrea Ernst, S. Rasoulinejad, Sarah Koellner, Ann-Kathrin Schneider, Marcin Luzarowski, Nicole Lübbehusen, Di Wu, A. Kannt et al. · 2026 · Communications Biology
56. Pharmacotherapy of type 1 diabetes – part 3: tomorrow
    Marc Rendell · 2025 · Expert Opinion on Pharmacotherapy
57. Validation of an Analytical Procedure for Evaluating the Biological Activity of a Medicinal Product Based on Tocilizumab and Determination of Acceptance Criteria for Test Results
    Yu. A. Nikonova, S. Abbasova, P. E. Kargopolova, O. Strizhakova, I. Lyagoskin, A. Vasilev, A. Pershin · 2024 · Regulatory Research and Medicine Evaluation
58. Short-Term Efficacy and Safety of Subcutaneous Tocilizumab in Rheumatoid Arthritis Patients in Pakistan: A Real-World Experience
    Tashia Malik, M. A. Saeed, Sumera Ghani, N. Butt, Sumaira Farman Raja, Nighat Mir Ahmed · 2023 · Pakistan Armed Forces Medical Journal
59. Präoperative Anämie beim Rheumatiker
    Lena Böhm, Marc Schmalzing, Patrick Meybohm · 2022 · Zeitschrift für Rheumatologie
60. Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
    D. Pappas, T. Blachley, J. Best, S. Zlotnick, W. Reiss, K. Emeanuru, J. Kremer · 2021 · Rheumatology and Therapy
61. Response to: ‘Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’’ by Pethoe-Schramm et al
    I. Shafran, F. Alasti, J. Smolen, D. Aletaha · 2020 · Annals of the Rheumatic Diseases
62. Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies
    M. Koehm, M. McIntosh, M. W. Hofmann, Varghese Abraham, C. Gabay, E. Choy, A. Kavanaugh, H. Burkhardt, F. Behrens · 2020 · Rheumatology International
63. Surveillance de la charge virale des virus Epstein-Barr (EBV), cytomégalovirus (CMV) et de la varicelle (VZV) chez les patients traités par tocilizumab pour la polyarthrite rhumatoïde
    C. Mourgues, C. Henquell, Zuzana Tatar, B. Pereira, Cynthia Nourisson, A. Tournadre, M. Soubrier, M. Couderc · 2017
64. Evaluation of safety, efficacy and post‐cessation efficacy durability of tocilizumab in patients with active rheumatoid arthritis
    A. Ahmadzadeh, Alireza N. Farahmand, L. Gachkar · 2017 · International Journal of Rheumatic Diseases
65. Terapia biológica en enfermedades reumatológicas
    M. Ugarte-Gil, E. Acevedo-Vásquez, G. Alarcón · 2013 · Revista Médica Herediana
66. Promise and pitfalls of kinase inhibitors for rheumatoid arthritis
    S. Cohen · 2012
67. Anti-Inflammatory Therapeutic Approaches
    Z. Szekanecz, G. Kerekes, Y. Shoenfeld · 2012 · Springer eBooks
68. Les applications en rhumatologie: en génomique
    P. Dieudé, H. Garchon · 2011
69. Die Nierenbeteiligung bei Rheumatoider Arthritis
    K. Triantafyllias, F. Korf, A. Schwarting · 2011 · Aktuelle Rheumatologie
70. New Therapeutic Options in Rheumatoid Arthritis: A Focus on Interleukin-6 Blockade
    N. Furfaro · 2011 · Journal of Infusion Nursing
71. Tocilizumab for rheumatoid arthritis: results of the Phase III clinical trial program
    J. Rueda, M. González-Gay, R. Blanco · 2011
72. Eficacia de los agentes anti-TNFα en una cohorte de pacientes con artritis reumatoide en Costa Rica
    José Francisco Díaz-Coto, Francisco Brenes Silesky · 2010
73. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Challenges in clinical trial design in inflammatory arthritis.
    J. O'Dell · 2010 · Baillière's Best Practice & Research : Clinical Rheumatology
74. Review of Biologic Therapies
    R. Tehrani, R. Ostrowski, R. Hariman, W. Jay · 2009 · Neuro-Ophthalmology
75. Fibroblastos sinoviales
    Elena Izquierdo, José L. Pablos · 2013 · Seminarios de la Fundación Española de Reumatología
76. Cardiac Immunomodulation
    S. Könemann, Marcus Dörr, S. B. Felix · 2017 · Elsevier eBooks
77. Chapter 71 – Treatment of Rheumatoid Arthritis
    James R. O'Dell · 2017 · Elsevier eBooks
78. Tocilizumab Increases Serum Adiponectin and Reduces Serum Fatty Acid Binding Protein 4 in Patients With Rheumatoid Arthritis
    H. Urushima, Yasuaki Sanada, A. Ogata, M. Yoshida, Hsiaoyun Lin, K. Hagihara, M. Narazaki, Toshio Tanaka, Toshinori Ito, K. Maeda · 2014
79. 63 – Anticytokine Therapies
    Z. Tutuncu, A. Kavanaugh · 2013
80. Epidermal growth factor receptor inhibitor induces Interleukin-6 via NADPH oxidase enzymes in head and neck cancer cells
    Elise V. M. Fletcher · 2012
81. Disentangling the effects of tocilizumab on neutrophil survival and function
    T. Gaber, M. Hahne, C. Strehl, P. Hoff, Y. Dörffel, E. Feist, G. Burmester, F. Buttgereit · 2015 · Immunologic research
82. Fibroblast-like synoviocytes exacerbate autoimmune arthritis upon psychological stress in an IL-6–dependent manner
    Jun Tamura, Shigeru Tanaka, K. Etori, Daisuke Hashiba, Shuhei Kameda, Atsuko Tomikawa, R. Kikuchi, Tatsurou Takahashi, A. Saku, Hirotoshi Kawashima et al. · 2026 · Science Advances
83. Longitudinal clinical outcomes after the escalation of subcutaneous tocilizumab from every 2 weeks to once weekly in rheumatoid arthritis with inadequate disease control: A 52-week real-world observational study
    Masanori Sudo, Sayuri Takamura, A. Abe, H. Ishikawa, D. Kobayashi, K. Nakazono, A. Murasawa, Suguru Yamamoto, S. Ito · 2026 · BMC Rheumatology
84. Comparative safety of interleukin inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials
    Chang-Yi Liu, Ji-Cho Li, Can Huang, Bing Wang · 2026 · Frontiers in Immunology
85. Positive effects of tocilizumab in late-stage rheumatoid arthritis (clinical case)
    I. Bashkova, I. Madyanov · 2026 · Meditsinskiy sovet = Medical Council
86. Tocilizumab and Dexamethasone Reduce TNF‐α and IL‐33 and Oxidative Stress in Kidney Tissue in Oleic Acid‐Induced ARDS Model
    Huseyin Serkan Erol, B. Demirci, Mohammad Alhilal, Funda Terzi, Nazli Kelercioglu · 2026 · Journal of biochemical and molecular toxicology
87. Trajectory of lipid profiles in rheumatoid arthritis patients receiving tofacitinib: Evidence from the prospective CENTRA cohort
    Hong Huang, Y. Geng, Yong Fan, Juan Zhao, Zhuo-Li Zhang · 2026 · British Journal of Clinical Pharmacology
88. Clustering reveals diagnostic overlap between Still’s disease and a hyperinflammatory subset of seronegative rheumatoid arthritis
    Alexandre Mercier-Guery, T. El-Jammal, Nour El-Nayef, E. Massy, N. Fournier, P. Sève, C. Confavreux, Y. Jamilloux, Fabienne Coury · 2026 · Scientific Reports
89. Tocilizumab in German patients with RA: real-world evidence from the noninterventional studies ARATA and ICHIBAN
    C. Specker, F. Behrens, Dagmar Strotkamp · 2026 · EULAR rheumatology open
90. Ambient Air Pollution and Neuropsychiatric Disorders: Mediating Genetic Signatures Uncovered by Integrated Multi-omics Mendelian Randomization
    Qi-Neng Wang, Dan-Na Jia, Hai-Tong-Zhe Sun, Yu-Ming Guo, Ke-Ding Lu · 2025 · Atmospheric Environment
91. A Review on Therapies of Rheumatoid Arthritis Disease
    Kajal K. Warghude, Dipali R. Shirsath, Shrikrushana S. Narode, Prasad B. Mhaske, Asst Prof Vidya Anap · 2025 · International Journal of Advanced Research in Science, Communication and Technology
92. Haemophilus parainfluenzae Infection Presenting as Prosthetic Joint Infection of the Shoulder, Vertebral Osteomyelitis, and Iliopsoas Abscess During Tocilizumab Therapy: A Case Report
    Minoru Sakakiyama, Koji Hayashi, Rikuto Yoshimizu, Maho Hayashi, Katsunori Mizuno · 2025 · Cureus
93. The Role of IL-6 in Rheumatoid Arthritis: Mechanisms, Tocilizumab Efficacy, and Challenges in Treatment
    Rui Shao · 2025 · Highlights in Science Engineering and Technology
94. Mechanistic Insights From A Case of Giant Cell Arteritis Polymyalgia Rheumatica Spectrum Disease
    Octavia Nakos, Aurora M. T. Poon, David F. L. Liew, C. Owen · 2025 · International Journal of Rheumatic Diseases
95. Development and validation of a prediction model for serious infections in rheumatoid arthritis patients treated with tocilizumab in Japan
    T. Nanki, Tomohiro Yamaguchi, Kosei Umetsu, Ryunosuke Tanabe, N. Maeda, Minori Kanazawa, Yuko Furuno, Shinichi Matsuda, Shinya Takemoto, Keiko Asao et al. · 2025 · Clinical Rheumatology
96. Effect of aqueous leaf extract of Macaranga barterion selected haematological and biochemical indices of carrageenan -induced paw edema in Wistar albino rats
    D. Peters, Chimburuoma Goodness Amadib, Chukwuka Promise Ali · 2022 · International Journal of Scientific Research Updates
97. Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19
    N. Muravyeva, B. Belov · 2022 · Meditsinskiy sovet = Medical Council
98. High‐dose IgG suppresses local inflammation and facilitates functional recovery after olfactory system injury
    K. Nishida, M. Kobayashi, E. Ishigami, K. Takeuchi · 2022 · Annals of Clinical and Translational Neurology
99. Rational Drug Therapy of Peptic Ulcer Disease In Patients Admitted To Gastroenterology Ward of LRH Peshawar, Khyber Pakhtunkhwa, Pakistan
    Farrah Shams, N. Samoo, Fawad Ali, Faiza Nawaz, Uzma Asif, Alia Gul · 2022 · Pakistan BioMedical Journal
100. RATIONAL DRUG THERAPY OF PEPTIC ULCER DISEASE IN PATIENTS ADMITTED TO GASTROENTEROLOGY WARD OF LRH PESHAWAR KHYBER PAKHTUNKHWA, PAKISTAN
     Farrah Shams, N. Samoo, Fawad Ali, Faiza Nawaz, Alia Gul · 2022 · Pakistan BioMedical Journal